New HIV combo therapy shows promise in small Women's study
NCT ID NCT05281510
First seen Jan 18, 2026 · Last updated May 25, 2026 · Updated 20 times
Summary
This study tested the safety of two lab-made HIV antibodies (VRC07-523LS and CAP256V2LS) followed by an immune-boosting drug (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy (ART). The goal was to see if this combination could help control the virus. Participants were women from a specific HIV cohort, and the study focused on side effects and lab abnormalities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
FRESH Clinical Research Site: Females Rising through Education, Support and Health
Umlazi, 4066, South Africa
Conditions
Explore the condition pages connected to this study.